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Thrombotic thrombocytopenic purpura (TTP) is a rare blood disorder with an estimated
incidence of 4–5 cases per million people per year. It is characterized by small-vessel
platelet-rich thrombi that cause thrombocytopenia, microangiopathic hemolytic anemia
and organ damage. There are reports in literature that TTP and acute pancreatitis are
associated, indicating each can be the cause of the other. However, acute pancreatitis
triggering TTP is very rare. A 71 years old female presented with abdominal pain of 3
days, followed by dark urine. She had icteric sclera, petechial rash and mild epigastric
tenderness. Lab ﬁndings were signiﬁcant for hemolytic anemia, thrombocytopenia and
elevated lipase. CT of abdomen showed evidence of pancreatitis and cholelithiasis. After
admission, patient developed symptoms of stroke. Further investigation showed elevated
lactate dehydrogenase and normal coagulation studied with peripheral blood smear
showed 5–6 schistocytes/high power ﬁeld. Disintegrin and metalloproteinase with
thrombospondin motifs-13 (ADAMTS13) activity showed less than 3% with high
ADAMTS13 inhibitor 2.2. Patient required 6–7 weeks of daily plasmapheresis until she
showed complete response. Our patient presented with clinical features of pancreatitis
prior to having dark urine and petechial rash. Therefore, we strongly believe that our
patient had pancreatitis which was followed by TTP. Patient's ADMTS13 activity was 6%
after 10 plasma exchanges, signifying refractory TTP and higher risk for morbidity and
mortality. There are limited data and consensus on the management of refractory TTP.
TTP and acute pancreatitis are associated. However, refractory TTP following acute
pancreatitis is rarely mentioned in the literature. We would like to emphasize the
importance of having higher clinical suspicion of the association of both disease entities.1. Introduction
Thrombotic thrombocytopenic purpura (TTP) is a rare blood
disorder with an estimated incidence of about 4–5 cases per
million people per year[1]. It is characterized by small-vessel
platelet-rich thrombi that cause thrombocytopenia, micro-
angiopathic hemolytic anemia and sometimes organ damage
(neurologic dysfunction or kidney failure).There are reports in literature that TTP and acute pancreatitis
are associated, indicating each can be the cause of the other.
However, acute pancreatitis triggering TTP is very rare[2]. TTP is
a medical emergency that is almost always fatal if appropriate
treatment is not initiated promptly. We report a case of
treatment of refractory TTP following acute pancreatitis.
2. Case presentation
A71 years old Pakistani female presented with abdominal pain
of 3 days. The pain was mid epigastric, intermittent, radiating to
her back. The patient complained of bright red blood in the stool.
She also noticed dark urine but no dysuria, frequency or urgency.
The patient denied any other symptoms. She had a past medical
illness of hypertension. On physical exam, vital signs were within
normal range. Patient had mildly icteric sclera and petechial rashle under the CC BY-NC-ND license (http://
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epigastric area by deep palpation without guarding.
Laboratory investigation showed white blood cell of 9.39 K/
mm3, hemoglobin of 9.4 mg/dL, platelet of 28 K/mm3 and total
bilirubin of 5.1 mg/dL (indirect bilirubin of 4.5 mg/dL). Renal
function tests were within normal range. Patient had elevated the
level of lipase (2463) and CT of abdomen showed peripancreatic
fat stranding and small volume ascites suggestive of pancreatitis
and cholelithiasis.
Fewhours after admission, patient developed slurred speech that
lasted for 10 min for which head CT was done and indicated focal
hypodensity in the left cerebral peduncle of the midbrain. Further
investigation showed elevated lactate dehydrogenase (LDH)
(1564) and normal coagulation studies included prothrombin time/
international normalized ratio, partial thromboplastin time, d-dimer
and ﬁbrinogen. Peripheral blood smear was done to evaluate the
cause of thrombocytopenia and hemolytic anemia, which revealed
5–6 schistocytes per high power ﬁeld (Figure 1).Figure 1. Peripheral blood smear showing schistocytes.Plasmapheresis was urgently started with possible diagnosis
of TTP with ﬁndings of peripheral blood smear, thrombocyto-
penia, hemolytic anemia and neurological symptoms. Later on,
disintegrin and metalloproteinase with thrombospondin motifs-
13 (ADAMTS13) activity showed less than 3% (range: 68%–
163%) with high ADAMTS13 inhibitor 2.2 (range: < 0.4). Pa-
tient did not show initial response to daily plasma exchanges and
steroid, and then weekly rituximab was started. Only 2 cycles of
rituximab was given due to infection and other similar therapies
could not also be given for the same reason. Patient continued to
have low platelet with elevated LDH and indirect bilirubin and
ADAMTS13 post exchange also showed only 6%.
During her stay in the hospital, she received daily plasma ex-
changes (regular and cryopoor plasma) for 6–7 weeks, until she
showed complete response (normal platelet, LDH, indirect bili-
rubin and ADAMTS13 activity). However, patient's entire stay
was complicated with subdural hematoma (SDH), sepsis and
respiratory failure.
3. Discussion
Acquired thrombotic thrombocytopenic purpura is a primary
thrombotic microangiopathy caused by severe ADAMTS13deﬁciency (typically, activity < 10%) due to an inhibitory autoan-
tibody directed against ADAMTS13. The events that actually
trigger acute episodes of TTP are often unclear.
The pancreas is frequently involved in patients with TTP and
this was explained by platelet/ﬁbrin rich thrombi, causing
pancreatic ischemia and leading to pancreatitis[3]. Pancreatitis
can also trigger TTP due to inﬂammatory response, mediated
by cytokines, causing endothelial damage[4,5].
Our patient ﬁrst presented with sign and symptoms of
pancreatitis prior to having dark urine and petechial rash. The
etiology of pancreatitis in our patient is cholelithiasis which was
supported by CT scan ﬁndings. Therefore, we strongly believe
that our patient had pancreatitis which was followed by TTP.
The median interval between pancreatitis and developing TTP is
estimated to be 3 days[5], which was also seen in our patient.
Plasma exchange is the mainstay of treatment that has reduced
the mortality rate from 90% to as low as 10%[6], by removing the
autoantibody and restoring the ADAMTS13 activity. The number
of plasma exchange required to achieve remission is highly
variable (range: 0–50), and is longer in patients with detectable
inhibitory anti-ADAMTS13 antibodies, which was also re-
ﬂected in our case[7]. ADAMTS13 response to early plasma
exchange therapy in patients with acquired TTP has prognostic
value. Patients whose ADAMTS13 level failed to exceed 10%
by Day 7 tended to experience treatment of refractoriness or
death[8]. Our patient's ADMTS13 activity was 6% after 10
plasma exchanges, signifying refractory TTP and higher risk for
morbidity and mortality.
TTP for which treatment with plasma exchange and steroids
fails to produce a satisfactory response is considered refractory
TTP. There are limited data and consensus on the management
of refractory TTP patient. Our patient was started with rituximab
on the 2nd week of her stay while continuing plasma exchange
and steroid to patient who did not show response. Patients whose
disease does not respond to plasma exchange, high-dose steroids
and rituximab are rare.
Rituximab, a monoclonal antibody targeting the CD20 anti-
gen that presents on B lymphocytes, is often used in treating
refractory TTP with good response rates[9]. Increasing evidence
supports the use of rituximab in cases of refractory TTP and
recommends considering rituximab as part of ﬁrst-line therapy,
along with plasma exchange and steroids, in acute TTP with
neurological/cardiac pathology[10].
The patient developed SDH while in the hospital. Any con-
dition that results in a low platelet count could predispose a
patient to bleeding, including intracranial hemorrhage. The true
incidence of intracranial hemorrhage is unknown in thrombo-
cytopenic patients[11]. However, the presence of SDH in our
patient could be a rare complication of TTP.
Patient's platelet numbers started to rise and sustained above
150 K/mm3 (with normal range indirect bilirubin and LDH), and
ADAMTS13 level increased to 71% after 6–7 weeks of plasma
exchange indicating slow response.
4. Conclusion
TTP and acute pancreatitis are associated. However, re-
fractory TTP following acute pancreatitis is rarely mentioned in
the literature. We describe a case of a woman of 71 years old
who developed TTP after an acute pancreatitis episode, which
was refractory to plasma exchange, steroids and rituximab. We
would like to emphasize the importance of having higher clinical
Ebisa Bekele et al./Journal of Acute Disease 2016; 5(5): 434–436436suspicion of the association of both disease entities. The role of
rituximab as part of the initial treatment along with plasma ex-
change should be further investigated especially in TTP patient
like ours with acute neurological symptoms.
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